AUG 18, 2026 · JOURNAL ARTICLE
Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer
Advanced Science
First-in-class preclinical work demonstrating a novel nanoparticle approach in animal xenograft models; lacks human efficacy data, controlled comparators, and peer-reviewed publication details required for clinical translation.
Reported
Tumor inhibition rate in CDX mode…70%
Tumor inhibition rate in PDX mode…61%